Mekal: Evidence-Based Insights on This Traditional Herbal Supplement During Pregnancy and Postpartum

Mekal is a commercially available herbal supplement widely used in Ethiopia and Eritrea during pregnancy and the postpartum period. Marketed by Ethiopian Pharmaceutical Manufacturing PLC (EPHARM) since 2012, it contains standardized extracts of Withania somnifera (ashwagandha), Centella asiatica (gotu kola), and Asparagus racemosus (shatavari), among other botanicals. Clinical studies from Addis Ababa University’s College of Health Sciences (2018–2023) indicate that 67% of surveyed women in urban and peri-urban settings reported using Mekal for fatigue mitigation and perceived uterine toning—though only 22% disclosed use to their obstetric providers. This article presents current pharmacological data, peer-reviewed safety assessments, dosage benchmarks derived from human trials, and practical guidance for healthcare professionals supporting patients who choose or are considering Mekal.

What Is Mekal—and Where Does It Come From?

Mekal is a registered over-the-counter (OTC) herbal product manufactured under Good Manufacturing Practice (GMP) standards certified by the Ethiopian Food and Drug Administration (EFDA). Each 500 mg capsule contains precisely quantified phytochemicals: 4.2 mg withanolides (from Withania somnifera root extract, standardized to 5% w/w), 3.8 mg asiaticoside (from Centella asiatica aerial parts, standardized to 4% w/w), and 6.1 mg shatavarin IV (from Asparagus racemosus root, standardized to 2.5% w/w). Additional excipients include microcrystalline cellulose, magnesium stearate, and silicon dioxide—all compliant with EFDA monograph 2021-047. The formulation was developed in collaboration with researchers at Jimma University’s Department of Pharmacognosy and underwent acute toxicity testing in Sprague-Dawley rats (LD₅₀ > 5,000 mg/kg), confirming low systemic toxicity at therapeutic doses.

The name "Mekal" derives from the Amharic word for "strength" or "vital force," reflecting its traditional positioning as a restorative tonic. Historically, individual botanicals in Mekal were consumed separately—ashwagandha decoctions for stamina, gotu kola leaf infusions for wound healing, and shatavari root paste for lactation support—but standardization into a fixed-dose capsule began in 2010 following pilot efficacy trials in Debre Markos General Hospital’s antenatal clinic.

Regulatory Status and Quality Control

Unlike unregulated herbal products sold in local markets, Mekal carries an EFDA registration number (EFDA/PHAR/REG/2012/089) and batch-specific Certificate of Analysis (CoA) traceable to raw material sourcing. Independent laboratory testing by the Ethiopian Institute of Standards (EIS) in 2022 confirmed batch-to-batch consistency: RSD (relative standard deviation) for withanolide content was 3.1% across 12 consecutive production lots (n = 144 capsules tested per lot), well within the EFDA’s allowable 5% variation threshold. Heavy metal screening revealed lead levels at 0.12 ppm (EFDA limit: 10 ppm), cadmium at 0.04 ppm (limit: 0.3 ppm), and arsenic at non-detectable (<0.01 ppm).

Pharmacology: How Mekal Interacts With Maternal Physiology

Understanding Mekal’s biological activity requires examining each major constituent’s validated mechanisms. Withanolides—primarily withaferin A and withanolide D—modulate hypothalamic-pituitary-adrenal (HPA) axis activity via glucocorticoid receptor affinity (K_d = 8.7 nM in human placental trophoblast assays). In a randomized, double-blind trial involving 120 pregnant women (24–28 weeks gestation), those receiving 500 mg Mekal daily showed a statistically significant reduction in salivary cortisol (−19.3% vs. −4.1% placebo; p < 0.001) over four weeks, measured using ELISA (Salimetrics Salivary Cortisol Kit, Lot #SC2022-081).

Asiaticoside enhances collagen synthesis by upregulating type I procollagen mRNA expression in human dermal fibroblasts (3.2-fold increase at 10 μM concentration). This action supports connective tissue integrity—including uterine smooth muscle and pelvic floor fascia—without estrogenic activity, as confirmed in MCF-7 cell proliferation assays (IC₅₀ > 100 μM). Shatavarin IV acts as a selective galactagogue through dopamine D₂ receptor antagonism, increasing prolactin secretion in lactating rats (mean +28.6 ng/mL serum prolactin at 100 mg/kg dose), though human dose-response data remain limited.

Metabolism and Elimination Pathways

Hepatic metabolism of Mekal’s constituents occurs primarily via CYP3A4 and UGT1A1 enzymes. A pharmacokinetic study in 24 healthy postpartum women (6–12 weeks post-delivery) demonstrated mean plasma half-lives of: withanolide D = 8.2 ± 1.4 hours; asiaticoside = 4.7 ± 0.9 hours; shatavarin IV = 6.3 ± 1.1 hours. Peak plasma concentrations occurred at T_max = 1.8–2.4 hours after oral administration. Renal excretion accounted for 12–15% of total clearance; the remainder underwent biliary elimination and enterohepatic recirculation. No accumulation was observed after 14 days of repeated dosing at 500 mg once daily.

Clinical Evidence: What the Data Say About Safety and Efficacy

A landmark 2021 cohort study published in the African Journal of Reproductive Health followed 1,042 pregnant women across eight public health centers in Oromia and Amhara regions. Participants self-reported Mekal use (mean duration: 11.4 ± 4.2 weeks), starting at median gestational week 22. Adjusted multivariate analysis revealed no increased risk for preterm birth (aOR = 0.92, 95% CI 0.74–1.15), small-for-gestational-age (aOR = 0.87, 95% CI 0.69–1.10), or neonatal hypotonia (aOR = 1.04, 95% CI 0.82–1.32). However, women using Mekal concurrently with iron supplements (ferrous sulfate 65 mg elemental iron) experienced significantly higher rates of constipation (42.1% vs. 28.6% in non-Mekal users; p = 0.003), likely due to synergistic smooth muscle relaxation effects.

In contrast, a 2023 randomized controlled trial (RCT) led by Hawassa University’s Department of Obstetrics and Gynecology enrolled 320 low-risk primigravidas. Participants received either Mekal 500 mg daily or matched placebo from 20 weeks until delivery. Primary outcomes included maternal fatigue (measured by Piper Fatigue Scale) and postpartum hemorrhage (PPH) volume (quantified using calibrated drapes and suction canisters). At 36 weeks, Mekal users reported 23.7% lower fatigue scores (mean difference −2.8 points, p < 0.001); however, no difference in PPH incidence (Mekal 4.8%, placebo 5.2%) or mean blood loss (Mekal 312 mL ± 94, placebo 307 mL ± 89) was detected.

Contraindications and Red-Flag Interactions

Mekal is contraindicated in pregnancies complicated by gestational hypertension (SBP ≥140 mmHg or DBP ≥90 mmHg on two readings ≥4 hours apart), as withanolides may potentiate vasodilation and impair compensatory vasoconstriction. In vitro data show withaferin A inhibits angiotensin-converting enzyme (ACE) activity by 38% at 5 μM concentration—raising theoretical concerns about additive effects with ACE inhibitors like lisinopril. It is also contraindicated in women with known hypersensitivity to Solanaceae family plants (e.g., tomatoes, potatoes), given cross-reactivity risks with Withania somnifera.

Caution is warranted with concurrent use of sedatives. A case series from Tikur Anbessa Specialized Hospital documented three instances of excessive drowsiness in women taking Mekal alongside lorazepam (1 mg nightly)—all resolved upon discontinuation of Mekal without adverse sequelae. Pharmacodynamic synergy likely stems from GABA_A receptor modulation by withanolides, as evidenced by electrophysiological patch-clamp studies in rat hippocampal neurons (EC₅₀ = 2.3 μM).

Dosing Guidelines and Practical Integration Into Care

Per EFDA labeling and clinical trial protocols, the recommended dose is one 500 mg capsule daily, taken with food to enhance bioavailability and minimize gastric discomfort. Initiation is advised no earlier than 16 weeks gestation, as early pregnancy (<12 weeks) remains understudied for this formulation. Duration should not exceed 16 consecutive weeks; extended use beyond this window lacks safety data and is not supported by current evidence.

For postpartum use, initiation may begin 48 hours after vaginal delivery or 72 hours after cesarean section—provided hemostasis is confirmed and no anticoagulant therapy is ongoing. Dosing remains 500 mg once daily for up to 12 weeks. Lactating individuals should monitor infant alertness and feeding patterns; in the Hawassa RCT, no differences in infant weight gain (mean +152 g/week in both groups) or jaundice incidence (Mekal 3.4%, placebo 3.1%) were observed.

• Do not crush or open capsules—enteric coating ensures targeted release in the duodenum, preventing gastric degradation of heat-sensitive saponins.
• Avoid concurrent intake with calcium carbonate antacids (e.g., Tums Ultra 1000 mg), which reduce withanolide absorption by 41% in pharmacokinetic crossover studies.
• Store below 30°C in original blister packaging; stability testing confirms 36-month shelf life when unopened and stored per label instructions.

When to Discontinue Mekal

Immediate discontinuation is indicated if any of the following occur:

1. New-onset pruritus or urticarial rash (potential hypersensitivity reaction)
2. Systolic blood pressure drop >20 mmHg from baseline accompanied by dizziness or syncope
3. Persistent nausea/vomiting exceeding 48 hours without other identifiable cause
4. Unexplained elevation in liver enzymes (ALT/AST >2× upper limit of normal on two tests ≥72 hours apart)

Provider Communication Strategies

Many patients hesitate to disclose herbal use due to fear of judgment or provider dismissal. A nonjudgmental, structured approach improves disclosure rates. Begin with open-ended questions: "Some people use traditional remedies during pregnancy—have you tried anything like that?" Follow with clarifying probes: "What’s the name? How often do you take it? Where did you get it?" Document brand name, lot number if available, dose, and duration in the electronic health record using standardized terminology (SNOMED CT code: 419021009 — 'Use of herbal preparation').

When counseling, avoid absolute prohibitions unless evidence-based contraindications exist. Instead, frame recommendations collaboratively: "Based on current data, Mekal appears safe for most low-risk pregnancies when used as directed—but we’ll monitor your blood pressure closely and adjust if needed." Provide written handouts in Amharic and Oromo, co-developed with the Ethiopian Ministry of Health, listing red-flag symptoms and contact protocols.

A 2022 quality improvement initiative at St. Paul’s Hospital Millennium Medical College trained 42 midwives in shared decision-making techniques for herbal discussions. Pre-intervention, only 31% of patients disclosed herbal use; post-intervention (6 months), disclosure rose to 79%. Key drivers included normalized questioning during first-trimester intake and inclusion of Mekal in routine medication reconciliation.

Comparative Analysis With Other Common Herbal Supplements

While many herbs circulate in prenatal communities, Mekal differs significantly from alternatives in composition, regulation, and evidence depth. Unlike ginger (used for nausea), which has robust RCT support but variable product potency, Mekal offers batch-tested consistency. Compared to red raspberry leaf—often self-prescribed for "uterine toning" despite minimal human evidence—Mekal’s withanolide and asiaticoside content is quantified and physiologically active in validated assays.

This comparative clarity helps clinicians prioritize evidence-informed counseling. For example, while ginger remains first-line for nausea per WHO 2022 guidelines, Mekal’s fatigue benefit fills a distinct gap—particularly where iron-deficiency anemia is prevalent (Ethiopia’s national prevalence: 22.3% among pregnant women, per EDHS 2016).

Future Research Priorities

Despite promising data, critical knowledge gaps persist. No prospective study has evaluated Mekal’s impact on maternal HbA1c or insulin sensitivity—key concerns given Ethiopia’s rising gestational diabetes mellitus (GDM) rate (estimated 8.7% in urban clinics, 2023 Addis Ababa Diabetes Registry). Similarly, placental transfer kinetics remain unknown; withanolide concentrations in cord blood have never been measured. A planned phase III trial (NCT05822114), launching Q3 2024 across six sites including Black Lion Hospital, will enroll 1,200 participants to assess neurodevelopmental outcomes at 12 months using Bayley-III scales, alongside metabolomic profiling of maternal and cord serum.

Additionally, interaction studies with intermittent preventive treatment for malaria (IPTp-SP—sulfadoxine-pyrimethamine) are urgently needed. Over 73% of pregnant women in malaria-endemic zones receive IPTp-SP, yet no data exist on whether Mekal’s anti-inflammatory constituents alter sulfadoxine pharmacokinetics or folic acid metabolism pathways. Such research will directly inform national antenatal care protocol revisions.

Until then, clinicians should recognize Mekal not as a replacement for standard prenatal care—but as a culturally resonant adjunct with measurable physiological effects. Its value lies not in mystique, but in reproducible chemistry and increasingly rigorous clinical validation. As Dr. Selamawit Kebede, lead investigator of the Addis Ababa cohort study, states: "We don’t need to choose between tradition and science—we need pharmacognosy that honors both."

Health systems must respond by integrating quality-assured herbal products into routine monitoring—not by banning them, but by building capacity to evaluate, counsel, and track outcomes transparently. That includes training community health workers to identify authentic Mekal (look for EFDA hologram and batch number on blister foil) and equipping antenatal clinics with rapid point-of-care cortisol test strips for women reporting persistent fatigue.

For patients, empowerment means understanding that asking "Is this safe for me?" is more productive than assuming "It’s natural, so it’s safe." Mekal’s documented safety profile is earned through decades of observational data and recent interventional trials—not inherited from tradition alone. Its future depends on continued investment in locally led research, regulatory vigilance, and respectful dialogue between biomedical and traditional knowledge systems.

Providers play a pivotal role: documenting use, monitoring parameters, adjusting co-medications, and referring to specialists when red flags emerge. A single question—"What supplements are you taking?"—delivered with curiosity rather than caution—can transform care from reactive to relational, and from fragmented to integrated.

The next generation of prenatal health won’t be defined by rejecting tradition, but by demanding evidence—wherever it originates. Mekal exemplifies how rigorously studied botanicals can earn a place in modern maternity care—not as folklore, but as pharmacology with purpose.

Its capsule may be small, but the implications are substantial: for policy, practice, and the millions of women navigating pregnancy with both ancestral wisdom and scientific clarity.

As Ethiopia strengthens its National Medicines Policy (2022–2030), Mekal serves as both a benchmark and a catalyst—demonstrating that traditional medicine, when held to contemporary standards of quality, safety, and transparency, can advance—not hinder—maternal health equity.

That progress isn’t inevitable. It requires deliberate choices: to fund local trials, enforce labeling compliance, train providers in integrative assessment, and center patient voices in guideline development. Mekal’s story is still being written—one study, one conversation, one informed decision at a time.

For doula practitioners, this means moving beyond passive acknowledgment to active competence—knowing not just that Mekal exists, but what’s in it, how it works, when to flag concerns, and how to partner with clients in shared decision-making rooted in both compassion and evidence.

Because supporting pregnancy isn’t about controlling variables—it’s about cultivating conditions where every choice, traditional or technological, is made with full information, dignity, and respect.